Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.37	$3.32	$2.70 ▼ $4.72	$646.03M	0.86	650,374 shs	493,819 shs
GHRS GH Research	$12.77 +1.7%	$13.90	$6.00 ▼ $20.50	$653.47M	0.98	432,270 shs	163,277 shs
TVGN Semper Paratus Acquisition	$0.98 -3.0%	$1.15	$0.26 ▼ $3.09	$185.73M	-0.77	1.64 million shs	680,884 shs
ZVRA Zevra Therapeutics	$8.90 -5.6%	$10.55	$6.19 ▼ $13.16	$529.35M	1.87	1.30 million shs	3.39 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-0.88%	+7.67%	+9.42%	-8.42%
GHRS GH Research	+1.67%	+5.54%	-20.14%	+16.30%	+29.78%
TVGN Semper Paratus Acquisition	-2.97%	+12.76%	-18.33%	-13.27%	+35.15%
ZVRA Zevra Therapeutics	-5.62%	-26.63%	-30.41%	+2.77%	+27.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.5881 of 5 stars	3.5	1.0	3.0	2.5	0.6
GHRS GH Research	3.0588 of 5 stars	3.5	3.0	3.9	2.5	0.0
TVGN Semper Paratus Acquisition	3.7655 of 5 stars	3.5	3.0	2.4	2.5	0.0
ZVRA Zevra Therapeutics	2.4517 of 5 stars	3.6	3.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.20% Upside
GHRS GH Research	3.00	Buy	$32.00	150.59% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$10.00	920.41% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	166.45% Upside

Current Analyst Ratings Breakdown

Latest TVGN, ZVRA, ABUS, and GHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/4/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	104.70	N/A	N/A	$0.43 per share	7.84
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A
ZVRA Zevra Therapeutics	$23.61M	21.16	N/A	N/A	$2.09 per share	4.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	N/A
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	N/A
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	N/A	44.50	N/A	4.33%	-112.40%	-37.67%	N/A

Latest TVGN, ZVRA, ABUS, and GHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$1.43	-$0.06	-$1.49	$1.21	$22.49 million	$25.88 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
GHRS GH Research	N/A	29.49	29.49
TVGN Semper Paratus Acquisition	N/A	0.35	0.35
ZVRA Zevra Therapeutics	0.52	7.85	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
GHRS GH Research	56.90%
TVGN Semper Paratus Acquisition	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
GHRS GH Research	41.60%
TVGN Semper Paratus Acquisition	73.24%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A
ZVRA Zevra Therapeutics	20	56.13 million	53.37 million	Optionable

TVGN, ZVRA, ABUS, and GHRS Headlines

Recent News About These Companies

JMP Securities Has Lowered Expectations for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

3 hours ago | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14 at 6:29 PM | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest Position

August 14 at 7:31 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Analyst Downgrade

August 14 at 2:21 AM | americanbankingnews.com

Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability

August 14 at 2:05 AM | tipranks.com

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.

August 13 at 12:59 PM | msn.com

Zevra Therapeutics: Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

August 13 at 7:57 AM | finanznachrichten.de

Zevra Therapeutics falls as significant earnings miss overshadows revenue beat

August 13 at 2:57 AM | investing.com

Zevra Therapeutics Reports Strong Q2 2025 Results

August 12 at 12:25 AM | tipranks.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

August 12 at 9:01 PM | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

August 12 at 6:51 PM | zacks.com

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

August 12 at 4:05 PM | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus PT from Brokerages

August 12 at 2:31 AM | americanbankingnews.com

Those who invested in Zevra Therapeutics (NASDAQ:ZVRA) three years ago are up 102%

August 11, 2025 | finance.yahoo.com

Zevra Therapeutics Q2 2025 Earnings Preview

August 11, 2025 | msn.com

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

August 11, 2025 | zacks.com

Zevra Therapeutics (ZVRA) Projected to Post Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Brokerages

August 10, 2025 | marketbeat.com

What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'

August 8, 2025 | zacks.com

Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

August 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, ZVRA, ABUS, and GHRS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.37 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.40 +0.02 (+0.74%)

As of 08/14/2025 07:39 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

GH Research NASDAQ:GHRS

$12.77 +0.21 (+1.67%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$12.71 -0.06 (-0.47%)

As of 08/14/2025 07:54 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Semper Paratus Acquisition NASDAQ:TVGN

$0.98 -0.03 (-2.97%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.99 +0.01 (+1.02%)

As of 04:47 AM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Zevra Therapeutics NASDAQ:ZVRA

$8.90 -0.53 (-5.62%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$8.90 -0.01 (-0.06%)

As of 04:04 AM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time